Research programme: immunomodulators - Boston BiomedicalAlternative Names: Immune response modifier - Boston Biomedical
Latest Information Update: 14 Sep 2016
At a glance
- Originator Boston Biomedical
- Class Antineoplastics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Sep 2016 Preclinical trials in Cancer in USA (Parenteral) before September 2016